T, Augmentation in Major Depressive Disorder: Safety Considerations

Lisa J. Rosenthal, M.D.; Whitney S. Goldner, M.D.; John P. O’Reardon, M.D.

From the Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago; the Department of Psychiatry, University of Pennsylvania, Philadelphia; and the Department of Medicine, University of Nebraska Medical Center, Omaha.

Received March 9, 2010; revision received Jan. 7, 2011; accepted Jan. 31, 2011.

Dr. O’Reardon has received research support or speaking or consulting fees from AstraZeneca, Bristol-Myers Squibb, CenRx Biopharma, Cyberonics, Eli Lilly, IC Axon, Magstim, Medtronic, and Neuronetics. Drs. Rosenthal and Goldner report no financial relationships with commercial interests.

From the Department of Psychiatry and Behavioral Sciences, Northwestern University, Chicago; the Department of Psychiatry, University of Pennsylvania, Philadelphia; and the Department of Medicine, University of Nebraska Medical Center, Omaha.

Address correspondence to Dr. Rosenthal (lrosenth@nmff.org).

Received March 9, 2010; Revised January 7, 2011; Accepted January 31, 2011.

Copyright © American Psychiatric Association


Many cases of major depression are difficult to treat, and effective options are an urgent priority. Triiodothyronine (T$_3$) has been used to augment or accelerate treatment of major depression, and while there is good evidence for its efficacy in the short term, there is a limited evidence base to guide long-term adjunctive use. In a collaborative case from the endocrinology and psychiatry perspectives, we review the evidence for the safety of this intervention. A case presentation from our clinical practice is used to illustrate issues of efficacy, adherence, and use in the setting of medical comorbidity, and suggested guidelines are presented for monitoring the safety of T$_3$ when used as longer-term augmentation.

Mechanism of Action of T, Augmentation

Abnormalities of thyroid regulation have been detected in many patients with depressive syndromes. Patients with major depression appear to have a higher incidence of subclinical thyroid abnormalities (1), and it is clear that diseases of the thyroid can have a profound effect on mood.

Thyroid hormone is important for protein synthesis and metabolism for virtually every organ, including the brain. The release of thyroid-stimulating hormone (TSH) from the anterior pituitary is regulated by thyroid-releasing hormone (TRH) from the hypothalamus. TSH in turn prompts the release of mainly levothyroxine (T$_4$), and to a lesser extent T$_3$, from the thyroid gland; T$_4$ is considered a "prohormone" with very little intrinsic activity and is transformed in the peripheral tissues into T$_3$, the biologically active form of thyroid hormone. Through negative feedback, pituitary TSH levels are regulated by the serum free T$_4$ and free T$_3$, and even subtle changes often lead to substantial changes in TSH levels, making TSH a particularly useful screening test for hypothalamic-pituitary-thyroid (HPT) axis function (2).

T$_3$ acts in the cell nucleus, stimulating gene expression and energy metabolism in cells in every organ and potentially enhancing neurogenesis in the CNS (2). T$_3$, both alone and in combination with fluoxetine, modulates gene transcription, with changes in mRNA coding for the 5-HT$_1A$ and 5-HT$_2A$ receptors (3). In the CNS, T$_4$ conversion to T$_3$ occurs intracellularly, which may be why T$_3$ administration seems to have particular benefit in the treatment of affective disorders (4). The enzymes
responsible for the conversion of T₄ to T₃ are also different in the CNS, perhaps explaining individual responses to T₃ supplementation and the variability of symptoms in subclinical hypothyroidism. Cooper-Kazaz et al. (5) have demonstrated that genetic polymorphisms in the type 1 deiodinase (DIO1) gene, which assists in the conversion of T₄ to T₃, might help determine which patients will respond to T₃ augmentation.

It is also possible that T₃ acts directly as a neurotransmitter or that it directly influences neurotransmission through monoamines (3). Actions at noradrenergic, serotonergic, and beta-adrenergic neurons have all been demonstrated, largely through studies of hypo- and hyperthyroid states. Rodent studies have demonstrated serotonergic effects of T₃ and T₄, supporting the idea that serotonergic transmission is enhanced by normal thyroid functioning, potentially through desensitization of the 5-HT₂A autoreceptor (6). T₃ was initially thought to be active solely within the noradrenergic projection pathway, and it may serve as a co-transmitter with norepinephrine in the limbic system, but it has also been demonstrated in high concentrations in the serotonergic raphe nuclei and their projections (7).

Evidence Base for Thyroid Augmentation

T₃ in Conjunction With Tricyclic Antidepressants

Augmentation of antidepressants with T₃ is one of the oldest evidence-based treatments for major depressive disorder. In 1969, Prange et al. conducted a pivotal study (8) demonstrating that administration of liothyronine enhanced response to tricyclic antidepressants in patients with treatment-resistant depression. Thyroid function was monitored, but methods available at that time were not sensitive or specific. Based on ankle jerk reflexes and protein-bound iodine assays, patients in the study appeared to have elevated thyroid function after treatment. Many subsequent studies have confirmed the Prange et al. study’s finding of efficacy, but few have formally assessed the HPT axis during treatment.

The majority of the evidence base for use of T₃ is for its coadministration with tricyclics. Two meta-analyses of T₃ coadministration with tricyclics have been published, one reviewing acceleration trials (9) and the other augmentation trials (10). Acceleration is defined as the use of T₃ at commencement of antidepressant treatment to enhance and hasten response. Augmentation is the administration of T₃ in patients who are unresponsive or partially responsive to an adequate course of antidepressant treatment initiated previously.

Acceleration of antidepressant response with T3.

A meta-analysis by Altshuler et al. (9) of six double-blind, placebo-controlled studies (125 patients total) of T₃ acceleration of tricyclics was positive. By definition, these were short-term studies of 2 to 3 weeks, and none discussed the option of continuing T₃ once antidepressant response was achieved. In addition, many were conducted before the advent of more sensitive assays of thyroid functioning in the late 1980s. Three of these acceleration studies (11–13) obtained initial lab values of protein-bound iodine and looked at ankle jerk reflexes and serum T₄ binding, but none performed follow-up testing. No differences in baseline thyroid tests were found between patients who responded to T₃ and those who did not, but some authors speculated that there may have been subtle thyroid dysfunction in the responders that was undetectable by the assays. In addition, a significant gender effect was observed, with women responding more robustly than men. While women generally have been found to have higher rates of both comorbid depressive syndromes and thyroid disease, a consistent association has not been replicated.

Augmentation of antidepressant response with T3.
Aronson et al. (10) conducted a positive meta-analysis of T₃ augmentation of tricyclics, finding eight controlled clinical studies with 292 patients. The studies were up to 12 weeks long, and several performed baseline and follow-up modern thyroid assays (4, 14–16). One positive study in 1977 conducted initial thyroid screening and additionally tested the CSF monoamine metabolites 5-hydroxyindoleacetic acid and homovanillic acid, hypothesizing that the mechanism of treatment with T₃ was an increase of available monoamines (17). However, the study found no differences in CSF monoamine metabolites between the placebo and active T₃ groups or between responders and nonresponders to T₃.

Thase et al. (14) found no association between results of thyroid function tests or TRH stimulation testing at baseline and outcome in a subset of patients treated with T₃. Joffe and Singer (4) evaluated T₃ versus T₄ in a randomized trial and found significant changes after 3 weeks in T₃, T₄, free T₄, TSH, and T₃ resin uptake in both groups, but these changes were not positive predictors of response; the main finding was that T₃ was more effective than T₄ as an augmenter. A 2-week augmentation study of lithium and T₃ (15) found in 1993 that the two were equally effective and outperformed placebo, with baseline TSH documented as being within normal range.

T₃ in Conjunction With SSRIs
Recently a number of studies have examined the augmentation of selective serotonin reuptake inhibitors (SSRIs) with thyroid hormone, but the data are more limited than with tricyclics. A review by Cooper-Kazaz and Lerer (18) found that not enough data were available yet for a meta-analysis but that a positive trend was revealed when the available double- and single-blind studies were analyzed. Papakostas et al. (19) reported a negative meta-analysis using strict inclusion criteria and finding only three adequate double-blind, randomized, placebo-controlled studies. The Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (20) evaluated SSRI augmentation using either lithium or T₃ and found no statistical difference in efficacy between the treatments, but T₃ had superior tolerability and adherence. All of these studies were short term, with the longest (STAR*D) lasting 12 weeks.

Two studies of T₃ in combination with SSRIs included baseline and follow-up thyroid testing. In the first, Cooper-Kazaz et al. (21) compared sertraline (50–100 mg) combined with either T₃ (25–35 μg) or placebo in an 8-week study and found that the sertraline-T₃ combination produced superior response and remission rates. After 8 weeks of T₃ supplementation, the mean TSH level fell significantly from 1.70 μIU/ml at baseline to 0.28 μIU/ml in responders, whereas nonresponders had mean pre- and posttreatment levels of 1.88 μIU/ml and 0.76 μIU/ml, respectively; responsiveness to treatment was significantly correlated (p=0.01) with the change in TSH level, suggesting that the therapeutic benefit could have been due to changes in the thyroid axis in this population. In a post hoc analysis, baseline T₃ levels in patients who responded to T₃ augmentation were significantly lower than in those who did not respond (107.60 ng/dl compared with 137.4 ng/dl, p=0.002). There was also a small but significant decline in TSH levels in the placebo group.

A combination study by Appelhof et al. (22) in which 124 patients were randomly assigned to receive paroxetine combined with 25 μg of T₃, 50 μg of T₃, or placebo showed a statistically significant dose-dependent increase of T₃ levels along with lowered T₄ (the final T₄ levels after 8 weeks of treatment were 0.9 pmol/liter in the placebo group, 0.6 pmol/liter in the 25-μg T₃ group, and 0.4 pmol/liter in the 50-μg T₃ group). Significant changes in thyroid function on testing were associated with significant side effects in nine of 28 patients in the 50-μg group, including sweating, tremor, nervousness, and palpitations, but there were no significant differences between the 25-μg T₃ and placebo groups. It is possible that noradrenergic effects of paroxetine due to norepinephrine transporter blockade exacerbated somatic symptoms that were consistent with a hyperthyroid state. Efficacy outcome was negative, with no differences between placebo and the two T₃ groups.

While T₃ compared well with lithium in STAR*D (20), and results with T₃ as an augmentation or combination strategy are encouraging, more controlled trials are needed to fully determine the efficacy of T₃ in combination with SSRIs.
In a study of pre- and postmenopausal women on high-dosage T_4 (not T_3) for bipolar disorder or major depressive disorder, Gyulai et al. (23) found no significant differences in bone density after at least 1 year of treatment (with several patients having up to 5 years of treatment), but they noted a nonsignificantly greater decline in bone density in postmenopausal women. Prior to follow-up scanning for bone density, the mean TSH level on high dosages of T_4 (300–500 μg/day) was normal at 0.4 μIU/ml. Similarly, Kelly and Lieberman (24) administered up to 150 μg of T_3 daily to 14 patients for an average duration of 24 months, and no cardiac or skeletal sequelae were detected.

**Safety: The Perspective From Endocrinology**

There is no consensus in endocrinology on use of thyroid hormone for the treatment of depression in euthyroid patients. When treating patients with hypothyroidism, endocrinology guidelines generally recommend using T_4 monotherapy (25). Multiple studies, including a meta-analysis, have evaluated the difference between T_4 monotherapy and T_3/T_4 combination therapy for the treatment of hypothyroidism. Overall no meaningful statistical differences have been found between the two regimens (26–31). Nevertheless, some studies have reported patient preference for combination therapy that was not explained by symptom outcomes, neurocognitive changes, or quality-of-life assessments (27). In one study (28), 44% of the patients reporting a preference for combination therapy had a suppressed TSH level, suggesting overreplacement of thyroid hormone. A study from Denmark (32) evaluated T_4 monotherapy compared with combination T_3/T_4 therapy while maintaining equivalent TSH values. Quality-of-life scores and depression and anxiety rating scores were significantly better in seven of 11 categories with combined therapy compared with monotherapy, and 49% of patients preferred combination T_3/T_4 therapy, compared with 15% who preferred T_4 monotherapy.

In euthyroid patients, high T_3 dosages carry a higher risk of induction of hyperthyroidism. In this respect, preexisting hypertension, tachycardia, and hyperglycemia could all potentially be worsened by hyperthyroidism (33). Subclinical hyperthyroidism has also been associated with long-term side effects, including reduced bone mineral density and an increased risk of osteoporosis, especially in postmenopausal women (34, 35), and an increased risk of atrial arrhythmias (36). Thus, when thyroid hormones are used in treating depression, clinicians should closely monitor patients for biochemical or clinical evidence of hyperthyroidism.

Ideally, patients who are started on T_3 augmentation for a psychiatric disorder should be monitored in the same manner as patients with hypothyroidism. TSH, free T_4, and free T_3 levels should be measured regularly, as well as whenever there is a report of increased anxiety, tremor, palpitations, insomnia, or other symptoms suggestive of hyperthyroidism. Patients should also be monitored for other conditions that could be exacerbated by T_3 supplementation, including hypertension, tachycardia, osteopenia or osteoporosis, atrial arrhythmias, and hyperglycemia. Finally, it should be borne in mind that some beta-blockers influence thyroid hormone metabolism and plasma levels (37).

**Conclusions and Recommendations**

Pharmacologic augmentation strategies currently approved by the U.S. Food and Drug Administration for major depressive disorder are limited to the second-generation antipsychotics aripiprazole and quetiapine, both of which are associated with safety concerns in long-term use. Lithium is another guideline-recommended agent, but it does not have a better tolerability profile than T_3. Current textbooks and the 2010 APA guidelines (38) agree that there is good evidence for the use of T_3 in depressive syndromes, but largely do not mention monitoring of thyroid functioning. Schatzberg et al. (39) suggest use of T_3 in postmenopausal women or atypical depression and tapering augmentation after 60 days.

There is good evidence to suggest that T_3 administration is helpful in the treatment of depressive states, but only limited data are available on long-term safety. Few of the randomized controlled studies of T_3 included both initial and follow-up thyroid function testing; those that did such testing showed expected changes in the thyroid axis and were largely reassuring on the
issue of significant side effects. Many psychiatrists are nevertheless uncomfortable prescribing thyroid hormones to essentially euthyroid patients, and some of our colleagues in endocrinology may also find this practice controversial.

In clinical decision making, the risk to health and safety from partially or inadequately treated major depression must be weighed against any putative risks of treatment. Findings from the STAR*D effectiveness trials (40) and from a meta-analysis (41) have highlighted shortcomings in the efficacy of antidepressants, which reinforces the need for psychiatrists to be flexible and creative in crafting their pharmacotherapy interventions for many patients suffering with major depression. The clinical case presented here highlights the morbidity from persistent depression in one patient in whom, for metabolic reasons, other augmentation strategies were considered high risk. In the case of T₃ augmentation, based on the literature and our clinical experience, we would recommend the safety guidelines summarized in Figure 1.

FIGURE 1.
Recommended Safety Guidelines for T₃ Augmentation of Antidepressant Medication
1. Obtain baseline TSH, free T4, and free T3 levels prior to augmentation.

2. Recheck thyroid indices at 3 months and then every 6 months, or at intervals annually. The goal is for the TSH level to be at the lower limit of the normal range. Free T4 levels must remain within the normal range. If TSH is normal, free T4 levels can be measured at the upper limit of the normal range based on the severity of depressive symptoms and response to T3.

3. In the longer term, if the patient has a history of multiple episodes or significant treatment resistance, maintenance on T3 is reasonable as an open-ended treatment option. If TSH is less than 0.5 mIU/L, add T4 (0.5-1.3 ng/dL) to avoid hypothyroidism. If TSH is normal, T4 is necessary if the patient is below the normal reference range depending on clinical efficacy.

4. Document a discussion of the risk-benefit profile of long-term T3, augmentation, including potential cardiac and bone disease risk.

5. In postmenopausal women, bone density should be monitored with densitometry every 1 year. If bone density is decreased, should be supplemented with calcium (1000 mg/day) and vitamin D (400-1000 IU/day) supplementation.

6. Periodically reevaluate the risks and benefits of T3 supplementation focusing specifically on depressive symptoms or change in status of cardiovascular disease.
1. Obtain baseline TSH, free T₄, and free T₃ levels prior to augmentation.

2. Recheck thyroid indices at 3 months and then every 6 months, or at minimum annually. The goal is for the TSH level to be at least at the lower limit of the normal range (around 0.4 μIU/ml) or below in the absence of hyperthyroid symptoms. Free T₃ level can be maintained at the upper limit of the normal range based on the severity of depressive symptoms and response to T₃.

3. In the longer term, if the patient has a history of multiple episodes or significant treatment resistance, maintenance on T₃ is reasonable as an open-ended treatment option. If there are no symptoms of hyperthyroidism and no known cardiac disease, consider maintenance T₃ supplementation even if the TSH level is below the normal reference range, depending on clinical efficacy.

4. Document a discussion of the risk-benefit profile of long-term T₃ augmentation, including potential cardiac and bone disease risk.

5. In postmenopausal women, bone density should be monitored with densitometry every 2 years. If bone density is declining, referral for evaluation of osteoporosis should be made. Standard recommendations for all postmenopausal women also include calcium (1200 mg/day) and vitamin D (800–1000 IU/day) supplementation.

6. Periodically reevaluate the risks and benefits of T₃ supplementation, focusing specifically on depressive symptoms or change in status of cardiovascular disease.
References

1. Arem R; Cusi K: Thyroid function testing in psychiatric illness: usefulness and limitations. Trends Endocrinol Metab 1997; 8:282–287
   [PubMed] [CrossRef]


3. Lifschytz T; Segman R; Shalom G; Lerer B; Gur E; Golzer T; Newman ME: Basic mechanisms of augmentation of antidepressant effects with thyroid hormone. Curr Drug Targets 2006; 7:203–210
   [PubMed] [CrossRef]

   [PubMed] [CrossRef]

5. Cooper-Kazaz R; van der Deure WM; Medici M; Visser TJ; Alkelai A; Glaser B; Peeters RP; Lerer B: Preliminary evidence that a functional polymorphism in type 1 deiodinase is associated with enhanced potentiation of the antidepressant effect of sertraline by triiodothyronine. J Affect Disord 2009; 116:113–116
   [PubMed] [CrossRef]

   [PubMed]

   [PubMed] [CrossRef]

   [PubMed]
Altshuler LL; Bauer M; Frye MA; Gitlin MJ; Mintz J; Szuba MP; Leight KL; Whybrow PC: Does thyroid supplementation accelerate tricyclic antidepressant response? a review and meta-analysis of the literature. Am J Psychiatry 2001; 158:1617-1622 [PubMed] [CrossRef]

Aronson R; Offman HJ; Joffe RT; Naylor CD: Triiodothyronine augmentation in the treatment of refractory depression: a meta-analysis. Arch Gen Psychiatry 1996; 53:842-848 [PubMed] [CrossRef]

Wheatley D: Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry 1972; 26:229-233 [PubMed] [CrossRef]

Coppen A; Whybrow PC; Noguera R; Maggs R; Prange AJ Jr: The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry 1972; 26:234-241 [PubMed] [CrossRef]


Joffe RT; Singer W; Levitt AJ; MacDonald C: A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression. Arch Gen Psychiatry 1993; 50:387-393 [PubMed] [CrossRef]

Gitlin MJ; Weiner H; Fairbanks L; Hershman JM; Friedfeld N: Failure of T₃ to potentiate tricyclic antidepressant response. J Affect Disord 1987; 13:267-272 [PubMed] [CrossRef]


Papakostas GI; Cooper-Kazaz R; Appelhof BC; Posternak MA; Johnson DP; Klibanski A; Lerer B; Fava M: Simultaneous initiation (coinitiation) of pharmacotherapy with triiodothyronine and a selective serotonin reuptake inhibitor for major depressive disorder: a quantitative synthesis of double-blind studies. Int Clin Psychopharmacol 2009; 24:19–25

Nierenberg AA; Fava M; Trivedi MH; Wisniewski SR; Thase ME; McGrath PJ; Alpert JE; Warden D; Luther JF; Niederehe G; Lebowitz B; Shores-Wilson K; Rush AJ; STAR*D Study Team: A comparison of lithium and T₃ augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry 2006; 163:1519–1530

Cooper-Kazaz R; Apter JT; Cohen R; Karagichev L; Muhammed-Moussa S; Grupper D; Drori T; Newman ME; Sackeim HA; Glaser B; Lerer B: Combined treatment with sertraline and liothyronine in major depression: a randomized, double-blind, placebo-controlled trial. Arch Gen Psychiatry 2007; 64:679–688

Appelhof BC; Brouwer JP; van Dyck R; Fliers E; Hoogendijk WJ; Huyser J; Schene AH; Tijssen JG; Wiersinga WM: Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. J Clin Endocrinol Metab 2004; 89:6271–6276

Gyulai L; Bauer M; Garcia-Espana F; Hierholzer J; Baumgartner A; Berghöfer A; Whybrow PC: Bone mineral density in pre- and post-menopausal women with affective disorder treated with long-term L-thyroxine augmentation. J Affect Disord 2001; 66:185–191

Baskin HJ; Cobin RH; Duick DS; Gharib H; Guttler RB; Kaplan MM; Segal RL; American Association of Clinical Endocrinologists: American Association of Clinical Endocrinologists medical guidelines for clinical practice for the evaluation and treatment of hyperthyroidism and hypothyroidism. Endocr Pract 2002; 8:457–469

Clyde PW; Harari AE; Getka EJ; Shakir KM: Combined levothyroxine plus liothyronine compared with levothyroxine alone in primary hypothyroidism: a randomized controlled trial. JAMA 2003; 290:2952–2958

Siegmund W; Spieker K; Weike AI; Giessmann T; Modess C; Dabers T; Kirsch G; Sänger E; Engel G; Hamm AO; Nauck M; Meng W: Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14:1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism. Clin Endocrinol (Oxf) 2004; 60:750–757

Appelhof BC; Fliers E; Wekking EM; Schene AH; Huyser J; Tijssen JG; Endert E; van Weert HC; Wiersinga WM: Combined therapy with levothyroxine and liothyronine in two ratios, compared with levothyroxine monotherapy in primary hypothyroidism: a double-blind randomized, controlled clinical trial. J Clin Endocrinol Metab 2005; 90:2666–2674

Escobar-Morreale HF; Botella-Carretero JI; Gómez-Bueno M; Galán JM; Barrios V; Sancho J: Thyroid hormone replacement therapy in primary hypothyroidism: a randomized trial comparing L-thyroxine plus liothyronine with L-thyroxine alone. Ann Intern Med 2005; 142:412–424


Ma C; Xie J; Huang X; Wang G; Wang Y; Wang X; Zuo S: Thyroxine alone or thyroxine plus triiodothyronine replacement therapy for hypothyroidism. Nucl Med Commun 2009; 30:586–593
Nygaard B; Jensen EW; Kvetny J; Jarløv A; Faber J: Effect of combination therapy with thyroxine (T\(_4\)) and 3,5,3'-triiodothyronine (T\(_3\)) versus T\(_4\) monotherapy in patients with hypothyroidism: a double blind, randomized cross-over study. Eur J Endocrinol 2009; 161:895–902

Osei K; Falko JM; O'Dorisio TM; Adam DR: Decreased serum C-peptide/insulin molar ratios after oral glucose ingestion in hyperthyroid patients. Diabetes Care 1984; 7:471–475


Cappola AR; Fried LP; Arnold AM; Danese MD; Kuller LH; Burke GL; Tracy RP; Ladenson PW: Thyroid status, cardiovascular risk, and mortality in older adults. JAMA 2006; 295:1033–1041

Wiersinga WM: Propranolol and thyroid hormone metabolism. Thyroid 1991; 1:273–277


Rush AJ; Trivedi MH; Wisniewski SR; Nierenberg AA; Stewart JW; Warden D; Niederehe G; Thase ME; Lavori PW; Lebowitz BD; McGrath PJ; Rosenbaum JF; Sackeim HA; Kupfer DJ; Luther J; Fava M: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163:1905–1917

[PubMed]
[CrossRef]


[PubMed]
[CrossRef]

Copyright © American Psychiatric Association